Pfizer announces that the second generation of EGFR-Tyrosine kinase inhibitors has landed in China
-
Last Update: 2021-02-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
lung cancer ranks first in the morbidity and mortality of all types of cancer in China. NSCLC accounts for about 85% of all lung cancer cases. EGFR is the most common mutation type in NSCLC patients in China, with about 50% of patients with late-stage EGFR mutation.Recently, Pfizer announced that the second generation of EGFR-Tyrosine kinase inhibitor (TKI) targeted drug dacotinib (commodity name: Dozerrun ®) has officially landed in China, and launched the EAR Lung Cancer Precision Academy to bring new precision treatment options to lung cancer patients.On May 15 this year, dacotinib tablets were approved by China's State Drug Administration (NMPA) and can be used for first-line treatment in patients with partial late stage or metastasis non-small cell lung cancer (NSCLC) patients with exosome loss mutation No. 19 exosome 19 or exon L858R replacement mutation No. 21.In September 2018, the U.S. Food and Drug Administration (FDA) granted priority vetting eligibility for the first-line treatment of patients with localized late stage or metastasis EGFR mutations.Currently, Dakota has been approved for first-line treatment of advanced lung cancer in the United States, the European Union, Japan, Canada, etc., and has been approved by regulators in China for almost simultaneous submission of applications and regulatory approval. (Drug Information Network)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
